The Food and Drug Administration (FDA) of the United States has approved the following PD-1/PD-L1 inhibitors for the treatment of TNBC: pembrolizumab for high-risk early-stage triple-negative breast cancer, pembrolizumab for locally recurrent, unresectable, or metastatic TNBC, and atezolizumab for PD-L1-positive positive unresectable, locally advanced, or metastatic TNBC (80). This evidence concerns the gene CD274 and triple-negative breast carcinoma.